CoChat

Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial

Open access
Armstrong, Matthew J, Barton, Darren, Gaunt, Piers, Hull, Diana, Guo, Kathy, Stocken, Deborah, Gough, Stephen C L, Tomlinson, Jeremy W, Brown, Rachel M, Hübscher, Stefan G, Newsome, Philip N, on behalf of the LEAN trial team · 2013 · BMJ Open
Cited by 51

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Abstract

Introduction: Non-alcoholic steatohepatitis (NASH) is now the commonest cause of chronic liver disease. Despite this, there are no universally accepted pharmacological therapies for NASH. Liraglutide (Victoza), a human glucagon-like peptide-1 (GLP-1) analogue, has been shown to improve weight loss, glycaemic control and liver enzymes in type 2 diabetes. There is currently a lack of prospective-controlled studies investigating the efficacy of GLP-1 analogues in patients with NASH. Methods and analysis: Liraglutide efficacy and action in NASH (LEAN) is a phase II, multicentre, double-blinded, placebo-controlled, randomised clinical trial designed to investigate whether a 48-week treatment with 1.8 mg liraglutide will result in improvements in liver histology in patients with NASH. Adult, overweight (body mass index ≥25 kg/m 2 ) patients with biopsy-confirmed NASH were assessed for eligibility at five recruitment centres in the UK. Patients who satisfied the eligibility criteria were randomly assigned (1:1) to receive once-daily subcutaneous injections of either 1.8 mg liraglutide or liraglutide-placebo (control). Using A'Hern's single stage phase II methodology (significance level 0.05; power 0.90) and accounting for an estimated 20% withdrawal rate, a minimum of 25 patients were randomised to each treatment group. The primary outcome measure will be centrally assessed using an intention-to-treat analysis of the proportion of evaluable patients achieving an improvement in liver histology between liver biopsies at baseline and after 48 weeks of treatment. Histological improvement will be defined as a combination of the disappearance of active NASH and no worsening in fibrosis. Ethics and dissemination: The protocol was approved by the National Research Ethics Service (East Midlands—Northampton committee; 10/H0402/32) and the Medicines and Healthcare products Regulatory Agency. Recruitment into the LEAN started in August 2010 and ended in May 2013, with 52 patients randomised. The treatment follow-up of LEAN participants is currently ongoing and is due to finish in July 2014. The findings of this trial will be disseminated through peer-reviewed publications and international presentations. Trial registration: clinicaltrials.gov NCT01237119 .

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bmjopen-2013-003995

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 26

  1. 10.1016/j.jhep.2011.03.020 · DOI · Paper page
  2. Bellentani, 1994, Prevalence of chronic liver disease in the general population of northern Italy: the Dionysos Study, Hepatology, 20, 1442, 10.1002/hep.1840200611 · DOI · Paper page
  3. 10.1002/hep.20466 · DOI · Paper page
  4. 10.1097/00042737-200411000-00002 · DOI · Paper page
  5. 10.1053/j.gastro.2010.09.038 · DOI · Paper page
  6. 10.1053/gast.2002.34168 · DOI · Paper page
  7. 10.1053/j.gastro.2011.06.061 · DOI · Paper page
  8. 10.1210/jc.80.3.952 · DOI · Paper page
  9. 10.1021/jm9909645 · DOI · Paper page
  10. 10.1111/j.1464-5491.2009.02666.x · DOI · Paper page
  11. 10.1136/bmj.c5062 · doi:10.1136/bmj.c5062
  12. 10.1016/j.jhep.2010.09.032 · DOI · Paper page
  13. 10.1152/ajpgi.00274.2011 · DOI · Paper page
  14. Ellrichmann, 2009, Sustained virological response during exenatide treatment in a patient with hepatitis C and nonalcoholic steatohepatitis, Am J Gastroenterol, 104, 3112, 10.1038/ajg.2009.444 · DOI
  15. 10.1111/j.1478-3231.2006.01315.x · DOI · Paper page
  16. 10.1002/hep.20701 · DOI · Paper page
  17. 10.1002/hep.24376 · DOI · Paper page
  18. 10.1016/0168-8278(95)80226-6 · DOI · Paper page
  19. 10.1002/hep.22724 · DOI · Paper page
  20. 10.1053/j.gastro.2004.08.052 · DOI · Paper page
  21. Armstrong MJ Corbett C Hodson J . Operator training requirements and diagnostic accuracy of Fibroscan in routine clinical practice. Postgrad Med J 2013. Published Online First: 7 Aug 2013. doi: 10.1136/postgradmedj-2012-131640 · DOI
  22. 10.1016/j.jclinepi.2007.08.008 · DOI
  23. 10.1002/sim.721 · DOI · Paper page
  24. 10.1056/NEJM200102153440706 · DOI · Paper page
  25. 10.1056/NEJMoa0907929 · DOI · Paper page
  26. 10.1002/hep.23314 · DOI · Paper page

Cited by

See all 51

Metadata

Authors
Armstrong, M. J., Barton, D., Gaunt, P., Hull, D., Guo, K., Stocken, D., Gough, S. C. L., Tomlinson, J. W., Brown, R. M., Hübscher, S. G., Newsome, P. N., & on behalf of the LEAN trial team
Venue
BMJ Open
Publisher
BMJ
Published
2013-11
Volume
3
Issue
11
Pages
e003995
ISSN
2044-6055 (ISSN-L)
OpenAlex
W2028279539
Cited by
51
References
27
FWCI
4.32
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.